TrialBMC medicine2023

Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).

Yuankai Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.